Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone

Angela C. Hirbe, Jessica Rubin, Özge Uluçkan, Elizabeth A. Morgan, Mark C. Eagleton, Julie L. Prior, David Piwnica-Worms, Katherine N. Weilbaecher

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


CXCR4 regulates hematopoietic and tumor cell homing to bone, but its role during osteoclast (OC) development is unknown. We investigated the role of CXCR4 in osteoclastogenesis and in a model of bone metastasis. Compared with controls, mice reconstituted with CXCR4 null hematopoietic cells exhibited elevated markers of bone resorption, increased OC perimeter along bone, and increased bone loss. CXCR4-/- OCs demonstrated accelerated differentiation and enhanced bone resorption in vitro. Furthermore, tumor growth specifically in bone was significantly increased in mice reconstituted with CXCR4-/- hematopoietic cells. Finally, enhancement of bone tumor growth in the absence of CXCR4 was abrogated with the OC inhibitor, zoledronic acid. These data demonstrate that disruption of CXCR4 enhances osteoclasto-genesis and suggest that inhibition of CXCR4 may enhance established skeletal tumor burden by increasing OC activity.

Original languageEnglish
Pages (from-to)14062-14067
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number35
StatePublished - Aug 28 2007


  • Bone metastasis
  • Osteoclast


Dive into the research topics of 'Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone'. Together they form a unique fingerprint.

Cite this